OncoMatch/Clinical Trials/NCT07124936
A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma
Is NCT07124936 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments for diffuse large b cell lymphoma (dlbcl).
Treatment: HDM2005 · Rituximab or Rituximab biosimilar · Gemcitabine · Oxaliplatin · Cyclophosphamide · Doxorubicin · Prednisone — The purpose of this phase 1b/2 study is to evaluate the safety, tolerability, and antitumor activity of HDM2005 in combination with standard of care in participants with diffuse large B-cell lymphoma. This study will include two arms: Cohort A (HDM2005 + R-GemOx) will enroll participants with relapsed/refractory DLBCL. Cohort B (HDM2005 + R-CHP) will enroll participants with untreated DLBCL. The study will consist of two parts: dose-escalation part and dose-expansion part.
Check if I qualifyExtracted eligibility criteria
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: allogeneic hematopoietic stem cell transplantation
Prior of allogeneic hematopoietic stem cell transplantation and has acute or ongoing graft-versus-host disease (GVHD) of any grade
Cannot have received: solid organ transplant
Prior solid organ transplant
Cannot have received: ROR1-targeted therapy
Prior ROR1-targeted therapy
Lab requirements
Blood counts
Adequate organ system and hematologic function as defined in protocol
Kidney function
Adequate organ system and hematologic function as defined in protocol
Liver function
Adequate organ system and hematologic function as defined in protocol
Adequate organ system and hematologic function as defined in protocol
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify